ArticleAmerican journal of translational research2025
Outcomes, neurological function, and inflammation indices following minimally invasive hematoma removal in hypertensive cerebral hemorrhage patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The predictive value of serum OX-LDL and 25-(OH)-D levels for cerebral edema in patients with hypertensive cerebral haemorrhage.Journal of medical biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of minimally invasive removal of intracranial hematoma (MIRICH) in the treatment of patients with hypertensive intracranial hemorrhage (HICH) and its effect on brain nerve function and body inflammation index.
methodsThis retrospective study involved 150 HICH patients treated at Shanghai Blue Cross Brain Hospital from January 2019 to March 2024. Patients were assigned into two groups according to the surgical approach they received: the control group (n = 75), treated with traditional craniotomy, and the observation group (n = 75), treated with MIRICH. The two groups were compared in terms of operative parameters, hematoma clearance rate, clinical efficacy, neurological function recovery, inflammatory markers, and postoperative complications. Risk factors affecting clinical efficacy were also analyzed.
resultsCompared to the control group, the observation group had significantly shorter operation and hospitalization times, less intraoperative blood loss, and a higher hematoma clearance rate (
conclusionMIRICH surgery can improve the hematoma clearance rate in HICH patients, with better clinical efficacy, and less trauma. Additionally, it promotes neurological function recovery, improves the prognosis and living ability of patients, and reduces the level of serum inflammatory factors. It is a promising treatment option worthy of wider adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.